Skip to main content
Clinical Trials/NCT01717625
NCT01717625
Completed
Phase 2

The Efficacy and Safety of Montelukast Sodium in the Prevention of Bronchopulmonary Dysplasia

Ajou University School of Medicine1 site in 1 country72 target enrollmentNovember 2011

Overview

Phase
Phase 2
Intervention
Montelukast
Conditions
Premature Birth
Sponsor
Ajou University School of Medicine
Enrollment
72
Locations
1
Primary Endpoint
Incidence of moderate to severe BPD or mortality
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

This study is multicentered, prospective, randomized, opened, parallel, intervention study.

The aim of this study is to evaluate the efficacy and safety of Montelukast sodium in the prevention of bronchopulmonary dysplasia (BPD) in preterm infant, below 32weeks gestational age.

The investigators evaluate the first effectiveness through the morbidity and mortality of bronchopulmonary dysplasia. And then, the investigators evaluate the second effectiveness through the oxygen index, the usage of mechanical ventilator about taking medicine after 2 Weeks, Oxygen Utilization After 4 Weeks, Proinflammatory Cytokine through the bronchial lavage fluid.

Registry
clinicaltrials.gov
Start Date
November 2011
End Date
October 2013
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Ajou University School of Medicine
Responsible Party
Principal Investigator
Principal Investigator

Lee Janghoon

Assistant professor

Ajou University School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Preterm infants born at less than 32 weeks
  • Birth 14 days after, oxygen or artificial ventilation who are using patient
  • more than 20cal/kg/d by enteral feeding
  • written consent of the parents

Exclusion Criteria

  • congenital anomaly
  • cardiovascular collapse
  • investigator's opinion

Arms & Interventions

Montelukast

montelukast sodium * dosage * \< 1000g : 0.5 mg/D QD * 1000g\~1500g : 1.0 mg/D QD * 1500g\~2000g : 1.5 mg/D QD * \> 2000g : 2mg/D QD * medication period : to discharge or GA 36wks

Intervention: Montelukast

Outcomes

Primary Outcomes

Incidence of moderate to severe BPD or mortality

Time Frame: corrected gestational age

At corrected gestational age 36 weeks, to compare the incidence of moderate to severe BPD or mortality

Secondary Outcomes

  • Oxygen Index. Use of mechanical ventilation, oxygen, systemic steroid. Weight gain, adverse event(1, 2, 4 weeks since starting study)

Study Sites (1)

Loading locations...

Similar Trials